Objective To investigate the curative effect of Oryz-Aspergillus Enzyme and Pancreatin Tablet (Combizym) combined with esomeprazole Magnesium Enteric-coated Tables (Esomeprazole) in the treatment of gastroesophageal reflux disease with dyspepsia.Methods 133 patients with gastroesophageal reflux disease and dyspepsia symptoms were randomly divided into two groups.Group A received esomeprazole 20mg once a day and Combizym 1 pill three times a day,while group B only received esomeprazole 20mg once a day.The symptoms integral,curative effect and adverse reaction in the two groups after treatment for 2 weeks and 4 weeks were compared.Results Compared with group B,the symptoms of abdominal distension and satiety significantly relieved after 2 weeks treatment in group A (abdominal distension x2 =4.516,P =0.038 ;satiety x2 =4.630,P =0.041),and one more symptom:loose stools relieved after treatment for 4 weeks in group A (abdominal distension x2 =5.317,P =0.025 ;satiety x2 =5.036,P =0.027 ; Loose stools x2 =4.989,P =0.030),while other symptoms didn t relieve (P ＞ 0.05).The total effective rate was 85.2％ vs 68.1％ (x2 =8.917,P =0.030) and 93.4％ vs 69.4％ (x2 =17.526,P =0.001)in gourp A and B after treatment for 2 weeks and 4 weeks respectively.The symptoms integral reduced notably no matter after 2 or 4 weeks treatment and decreased more significantly in group A (2 weeks t =6.355,P =0.000 ;4 weeks t =5.450,P =0.000).The total effective rate increased more significantly in group A,without serious adverse reaction in both two groups.Conclusion Combined combizym with esomeprazole can better improve the symptoms of gastroesophageal reflux disease with dyspepsia without obvious adverse reaction.

Objective To compare the clinical efficacy of ilaprazole standard triple therapy with omeprazole standard triple therapy in the treatment of patients with Helicobacter pylori ( Hp ) positive duodenal bulb ulcer. Methods 100 patients with Hp positive duodenal bulb ulcer were randomly divided into the two groups by lottery, given ilaprazole standard triple therapy and omeprazole standard triple therapy respectively.After 5 weeks of the course,take gastroscopy and the enzyme 13C-urea breath test,and the Hp eradication rate,clinical efficacy,ulcer heal-ing rate and adverse reactions were observed.Results The Hp eradication rate is better than the omeprazole group (92%vs 78%,χ2 =3.853,P<0.05),while the ulcer healing rate were no significant (96%vs 90%,χ2 =1.561, P>0.05).Conclusion It is a good method in the treatment of Hp positive duodenal bulb ulcer for ilaprazole stand-ard triple therapy.

Objective: To study the effect of oral metformin on the prognosis of patients with gastric cancer. Methods: The clinical data of 364 patients with gastric cancer admitted to the First Affiliated Hospital of Medical College of Shantou University from January 2013 to December 2017 were collected.The patients were divided into metformin group (31 cases), non-metformin group (35 cases) and non-diabetic group (298 cases) according to whether they were diabetes or treated with metformin.The mortality and survival of the three groups were compared. Results: The mortality rate was 12.9%(4/31) in the metformin group, 74.3%(26/35) in the non-metformin group, 52.0%(155/298) in the non-diabetic group, and the mortality rate in the metformin group was lower than that in the other two groups, the differences were statistically significant(χ²=10.081, P=0.001; χ²=7.681, P=0.006), and the metformin group had the lowest mortality rate.There was no statistically significant difference between the non-metformin group and the non-diabetic group (χ²=1.665, P=0.197). The survival time of the metformin group, non-metformin group and non-diabetic group were (29.017±16.254) months, (9.692±10.355) months and (16.748±8.526)months, respectively.The survival time of the metformin group was longer than that of the non-metformin group (t=5.827, P=0.000) and the non-diabetic group (t=6.843, P=0.000), and the survival time of the non-diabetic group was longer than that of the non-metformin group (t=4.523, P=0.000), and the overall survival of patients in the metformin group was prolonged.Clinical staging, treatment of gastric cancer, alcohol consumption and oral metformin treatment were independent factors influencing the prognosis of patients with gastric cancer. Conclusion Oral metformin can improve the prognosis of patients with gastric cancer and prolong the life of patients.